German Merck, Pfizer get FDA priority review for cancer drug
German drugmaker Merck KGaA and U.S. partner Pfizer have been granted priority review status in the United States as they seek approval to fight a rare and aggressive form of skin cancer with immunotherapy drug avelumab.

The U.S. Food and Drug Administration has accepted the request for approval and will review the trial data for the drug against metastatic Merkel cell carcinoma within six months instead of the usual 10, Merck said on Tuesday...